HemangioblastomaSymptoms, Doctors, Treatments, Advances & More
Hemangioblastoma Overview
Learn About Hemangioblastoma
View Main Condition: Brain Tumor
- Hemangioblastoma
Ophthalmology - Wills Eye Hospital
Carol Shields is an Ophthalmologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Shields is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. She is also highly rated in 50 other conditions, according to our data. Her clinical expertise encompasses Retinoblastoma, Melanoma of the Eye, Uveal Melanoma, Vitrectomy, and Iridectomy. Dr. Shields is board certified in Ophthalmology. Dr. Shields is currently accepting new patients.
Allan Levi is a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Levi is rated as a Distinguished provider by MediFind in the treatment of Hemangioblastoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Meningocele, Cervical Spondylosis, Spondylolisthesis, Laminectomy, and Spinal Fusion. Dr. Levi is currently accepting new patients.
UT MD Anderson Cancer Center
Eric Jonasch is an Oncologist practicing medicine in Cary, North Carolina. Dr. Jonasch is rated as an Elite provider by MediFind in the treatment of Hemangioblastoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Hemangioblastoma, Chromophobe Renal Cell Carcinoma, Hypothalamic Hamartomas, and Nephrectomy.
Summary: Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments. The goal is to determine whether the new 2021 WHO cl...
Summary: This is an exploratory study to assess \[18F\]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial. The main objective is to correlate hypoxia-inducible factor-2alpha (HIF2α) levels as determined by an investigational \[18F\]PT2385 PET/CT scan with the levels on subsequently obtained tissue by HIF2...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

